- Having been named Biologics CDMO of the Year, BioDlink presented its expertise regarding the globe’s first approved EGFR-targeted Antibody-Drug Conjugate (ADC) for recurrent or metastatic nasopharyngeal carcinoma.
- The firm facilitates smooth technology transfer between Europe and China, alongside accelerated biologics development, utilizing its unified, comprehensive Chemistry, Manufacturing, and Controls (CMC) platform.
SUZHOU, China, Nov. 28, 2025 — , a prominent international firm in biologics contract development and manufacturing, played a central role at Biologics CDMO Europe 2025. Here, it highlighted its vital contribution to the regulatory approval and production backing of the world’s inaugural approved EGFR-targeted antibody-drug conjugate (ADC) for managing recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
In his keynote address, titled “Linking Europe and China —Mutual Success in Biologics CMC Development,” Dr. Jian Zhang, BioDlink’s Chief Operating Officer, delved into both global and Chinese biologics market tendencies. He noted that by 2025, China accounted for 54 percent of ADCs and 48 percent of bispecific and trispecific antibodies in worldwide Phase Ⅰ/Ⅱ trials[1]. For the first three quarters of 2025, the nation’s total license-out deal value reached $920.3 billion, marking a 77 percent rise compared to 2024, with 16 of these deals exceeding $1 billion each, according to an industry analysis[2].
Dr. Zhang further presented BioDlink’s capabilities for executing projects across different regions, offering examples of how its integrated, single-base, complete Chemistry, Manufacturing, and Controls (CMC) platform streamlined technology transfer, ensured flexible regulatory compliance, and expedited manufacturing schedules. The company recently produced a pioneering Becotatug Vedotin injection, which garnered marketing authorization from China’s National Medical Products Administration (NMPA), standing as the first EGFR-targeted ADC to be approved worldwide and signifying a major stride in R/M NPC treatment.
Solidifying its leadership within the industry, BioDlink earned the title of Biologics CDMO of the Year at the Biologics CDMO Excellence Europe 2025 awards. This recognition was bestowed for its outstanding performance in biologics across essential client requirements such as quality, speed, and cost-effectiveness.
BioDlink provided sponsorship for the “Tech-Transfer Simplified: Lessons across the Lifecycle” forum, where Dr. Zhang engaged in a vibrant conversation with prominent biotech CEOs, multinational corporation executives, research heads, and investment leaders. The consensus was that technology transfer should be viewed not merely as a technical handover, but as a crucial strategic phase encompassing the shift from development to manufacturing, impacting product quality, scheduling, regulatory submissions, and commercial results. Furthermore, smooth technology transfer is vital for China’s evolution into a global innovation center, fostering increased speed, wider modality development, and a transition toward NewCo and out-licensing funding models.
“We are enabling our international clients to pursue innovation with greater confidence,” stated Dr. Zhang. “Leveraging our advanced facilities based in Asia, our strategic presence in Europe, and our proven quality systems, BioDlink acts as a pivotal connection point between Europe and China’s rapidly expanding drug discovery and CMC development landscape, offering substantial benefits in terms of pace and expense. We are dedicated to functioning as a strategic CDMO collaborator for pharmaceutical enterprises worldwide that are developing pioneering and other cutting-edge treatments.”
About BioDlink Biopharm Co., Ltd.
BioDlink (1875.HK) stands as a prominent international Contract Development and Manufacturing Organization (CDMO) focusing on biologics and bioconjugates (ADCs/XDCs). Its headquarters are located in Suzhou, with additional hubs in Shanghai and Beijing, offering comprehensive, integrated services from initial R&D stages to commercial-scale production.
Through its unified, single-base platform and exclusive technologies—including BDKcell® for accelerated cell line development and GL-DisacLink® for precise site-specific conjugation—BioDlink assists its collaborators in expediting development, enhancing operational efficiency, and lowering expenditures.
The company manages four commercial manufacturing lines equipped for large-scale sterile fill-finish operations. This is supported by a global quality system compliant with GMP, which has secured PMDA accreditation in Japan and facilitated product approvals in China, Indonesia, Nigeria, Pakistan, Colombia, and Bolivia.
Driven by its core tenets of “Quality First, Innovation Driven, Success Together,” BioDlink is dedicated to broadening worldwide access to next-generation biologics and forging reliable collaborations globally. To learn more, please visit:
Reference:
|
[1] McKinsey & Company, Building the bridge to global innovation report |
|
[2] Source from NextPharma® Database and MedAlpha® Database |
SOURCE BioDlink Biopharm Co., Ltd.